Contactless measurement of vital signs using a camera-based system
Remote Investigation and Assessment of Vital Signs
This study is testing a new camera system that measures vital signs like blood pressure and heart rate without touching the patient to see if it works well for everyone and helps reduce infection risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 860 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vastra Gotaland Region Government |
| Locations | 1 site (Ulricehamn) |
| Trial ID | NCT05022264 on ClinicalTrials.gov |
What this trial studies
This project evaluates a new camera-based system designed to measure vital signs such as blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature without physical contact. The study is structured into three work packages focusing on the validity and reliability of the device for different vital signs and across various skin types. Patients aged 18 and older attending primary or secondary healthcare settings will participate, providing informed consent for the assessment. The aim is to enhance the accuracy of vital sign measurements while minimizing the risk of infection transmission.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 and older attending primary or secondary healthcare who can provide informed consent.
Not a fit: Patients in severe medical conditions where a 15-20 minute delay in management could be detrimental will not benefit from this study.
Why it matters
Potential benefit: If successful, this technology could significantly reduce the risk of infection transmission while providing accurate vital sign measurements.
How similar studies have performed: While the approach of contactless vital sign measurement is innovative, similar studies have shown promise in improving patient safety and measurement accuracy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The same subject can't be enrolled more than once with the exception that subjects in WP1 may also be recruited to WP2. WP1+WP2: 1. The patient is attending primary or secondary health care. 2. The subject has provided informed consent. 3. Age ≥18 years. 4. Fluent in Swedish, English, Somali or Arabic (we will translate the patient information and ensure an interpreter can be present for translating questions). 5. The patient is willing and able to give informed consent ". 6. The investigator determines that the new study device, and the reference methods, can be used as intended with adequate safety. 7. The delay in the management of each patient introduced by this study is approximately 15-20 minutes. Patients deemed being in such a severe medical condition that 15-20 minutes of delay is deemed detrimental will not be included. WP3: 1. Patients attending primary health care. 2. The subject has provided informed consent. 3. Age ≥18 years. 4. Fluent in Swedish, English, Somali or Arabic (we will translate the patient information and ensure an interpreter can be present for translating questions). 5. The patient is willing and able to give informed consent . 6. The investigator determines that the new study device, and the reference methods, can be used as intended with adequate safety. 7. The delay in the management of each patient introduced by this study is approximately 15-20 minutes. Patients deemed being in such a severe medical condition that 15-20 minutes of delay is deemed detrimental will not be included. Exclusion Criteria: Subjects are free to withdraw from the study at any point. Subjects will also be withdrawn from the study in case of unexpected depressed level of consciousness from inclusion up until all investigations are completed (during approximately 15-20 minutes). Any reduction in consciousness will incur that the subject is withdrawn.
Where this trial is running
Ulricehamn
- Hälsobrunnen Vårdcentral — Ulricehamn, Sweden (Recruiting)
Study contacts
- Principal investigator: Ronny Gunnarsson, MD PhD — School of Public Health and Community Medicine, Gothengurg University, Sweden
- Study coordinator: Ronny Gunnarsson, MD PhD
- Email: ronny.gunnarsson@gu.se
- Phone: +46 31 786 6835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.